A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia
The purpose of this study is to confirm the efficacy and safety of fludarabine phosphate administered with dose increasing in 6 cycles (1 cycle: 5 treatment days every 28 days) in untreated chronic lymphocytic leukemia (CLL) patients with anemia and/or thrombocytopenia.
Leukemia, Lymphocytic, Chronic, B-Cell
DRUG: Fludarabine Phosphate (Fludara)
Response rate of final overall evaluation up to 6 treatment cycles (at about 6 months), Up to 6 treatment cycles (at about 6 months)
Response rate for measurable lesions / evaluable lesions / peripheral blood findings / bone marrow findings, Up to 6 treatment cycles (at about 6 months)|Duration of response and change of peripheral blood findings, End of study
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.